Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Valenzuela (Madrid, Spain), T. Maher (London, United Kingdom), F. Bonella (Essen, Germany), A. Pesci (Monza, Italy), S. Jouneau (F-35000 Rennes, France), N. Patel (New York, NY, United States of America), E. Fernández Pérez (Denver, CO, United States of America), R. Goeldner (Biberach, Germany), S. Stowasser (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), M. Quaresma (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France). Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial. 4577

Member's Comments

No comment yet.

Related content which might interest you: Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS trial Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Changes in FVC in the SENSCIS trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 The clinical significance of >5% change in VC in patients with idiopathic pulmonary fibrosis -extended analysis of the pirfenidone trial in Japan Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies Source: International Congress 2016 – IPF treatment I Year: 2016 Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia Year: 2020 Relationship between change in trough FEV1 and COPD patient outcomes: Pooled analysis of 23 clinical trials in patients with COPD Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 The magnitude of pirfenidone treatment effect in patients with idiopathic pulmonary fibrosis (IPF): A pooled analysis of outcomes in the CAPACITY (CAP) studies Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 Association between monocyte count and ILD progression in subjects with fibrosing ILDs: data from the INBUILD trial Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010